$7.10
2.09% today
Nasdaq, Apr 02, 09:13 pm CET
ISIN
US45780L1044
Symbol
INGN

Inogen, Inc. Stock price

$6.95
-1.18 14.51% 1M
-2.67 27.75% 6M
-2.22 24.21% YTD
-0.59 7.82% 1Y
-28.33 80.30% 3Y
-42.04 85.81% 5Y
-26.92 79.48% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-0.18 2.52%
ISIN
US45780L1044
Symbol
INGN
Sector

Key metrics

Market capitalization $184.38m
Enterprise Value $86.37m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.26
P/S ratio (TTM) P/S ratio 0.55
P/B ratio (TTM) P/B ratio 0.96
Revenue growth (TTM) Revenue growth 6.35%
Revenue (TTM) Revenue $335.71m
EBIT (operating result TTM) EBIT $-38.73m
Free Cash Flow (TTM) Free Cash Flow $-9.09m
Cash position $117.42m
EPS (TTM) EPS $-1.52
P/E forward negative
P/S forward 0.52
EV/Sales forward 0.24
Short interest 2.99%
Show more

Is Inogen, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Inogen, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Inogen, Inc. forecast:

1x Buy
25%
2x Hold
50%
1x Sell
25%

Analyst Opinions

4 Analysts have issued a Inogen, Inc. forecast:

Buy
25%
Hold
50%
Sell
25%

Financial data from Inogen, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
336 336
6% 6%
100%
- Direct Costs 170 170
4% 4%
51%
166 166
19% 19%
49%
- Selling and Administrative Expenses 165 165
1% 1%
49%
- Research and Development Expense 18 18
11% 11%
5%
-18 -18
64% 64%
-5%
- Depreciation and Amortization 21 21
16% 16%
6%
EBIT (Operating Income) EBIT -39 -39
42% 42%
-12%
Net Profit -36 -36
65% 65%
-11%

In millions USD.

Don't miss a Thing! We will send you all news about Inogen, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inogen, Inc. Stock News

Neutral
Business Wire
13 days ago
GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen To Present at 24th Annual Needham Virtual Healthcare Conference.
Positive
Seeking Alpha
about one month ago
Inogen's new management and strategy are yielding results, with better-than-expected 2024 performance and a more stable base from which to keep growing the B2B business. Despite weak DTC sales, strong B2B growth drove better-than-expected sales in Q4, and Inogen likewise beat on margins. Guidance disappointed investors and prompted a 15% drop in the shares, as moderately better revenue guidance...
Neutral
Seeking Alpha
about one month ago
Inogen, Inc. (NASDAQ:INGN ) Q4 2024 Earnings Conference Call February 25, 2025 5:00 PM ET Company Participants Ryan Peterson – Investor Relations Kevin Smith – President and Chief Executive Officer Mike Bourque – Chief Financial Officer Conference Call Participants Operator Welcome to Inogen's Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
More Inogen, Inc. News

Company Profile

Inogen, Inc . engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products consists of Inogen One G4 system, Inogen One G3 system, Inogen One G2 system, and Inogen at Home. The company was founded by Alison Perry, Alison Bauerlein, Brenton Taylor and Byron Myers on November 27, 2001 and is headquartered in Goleta, CA.

Head office United States
CEO Kevin Smith
Employees 766
Founded 2001
Website www.inogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today